Alector Q2 net income $9.9M, cash $808.9M; AL044 IND submitted

Alector, Inc.

2022-Q2 EPS reported -$0.42 revenue$104,325,000

Net income $9.9M ($0.12/share) vs net loss $55.1M ($0.69) in Q2 2021; collaboration revenue rose to $79.9M from $6.6M.
Cash, equivalents and investments $808.9M; estimated runway into second half of 2024.
IND submitted for AL044 targeting MS4A, a genetic risk locus for Alzheimer's; first study in healthy volunteers planned.
Expanding sites for INFRONT-3 Phase 3 of latozinemab in FTD-GRN; Phase 1 data for AL101 expected later 2022.
Peter Heutink appointed CSO; John Maraganore as strategic advisor; AbbVie terminates CD33 collaboration (AL003).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.